Macrophage colony-stimulating factor (M-CSF or CSF-1) and its cognate receptor, the tyrosine kinase c-fms, are essential for monocyte and macrophage development. We have recently identified an Fms-interacting protein (FMIP) that binds transiently to the cytoplasmic domain of activated Fms molecules and is phosphorylated on tyrosine by Fms tyrosine kinase. FMIP is a substrate not only for Fms but also for protein kinase C (PKC). Mutagenesis reveals that this occurs on serines 5 and 6. Adjacent to these sites is a nuclear localization signal (NLS). We show that this NLS is essential for the predominantly nuclear localization of FMIP. Generation of phosphomimetic substitutions on serine residues 5 and 6 confirms that PKC-mediated phosphorylation on this site leads to translocation of FMIP to the cytosol. Furthermore, the mutant FMIP (FMIPSS5,6AA) was detected abundantly in the nucleus even in the presence of activated PKCalpha. Wild-type FMIP and FMIPSS5,6AA inhibited M-CSF-mediated survival signaling, while FMIPS-S5,6EE-expressing cells survived and differentiated into macrophages more efficiently than wild-type cells in the presence of M-CSF or TPA. We conclude M-CSFmediated activation of PKCalpha can potentiate FMIP action to initiate survival/differentiation signaling.
Introduction
Although an increasing amount of knowledge is available regarding the molecular mechanisms that are responsible for proliferation of hematopoietic cells, little is known about the signaling events of lineage commitment or the differential effects of receptors governing hemopoiesis (Friedmann, 2002) . The receptor tyrosine kinase III family that includes stem cell factor (SCF) receptor, Flt3 and macrophage colony-stimulating factor (M-CSF, also termed CSF-1) receptor, c-Fms tyrosine kinase, is fundamental in regulating stem and progenitor cell growth and development. Yet, little is known about the differences in signal transduction manifest between these receptor types that are often expressed on the same cell type. Furthermore, the mutated forms of these receptors play a key role in the myeloid leukemias, indicating that an understanding of their biochemistry would be of value in the study of leukemogenesis. The M-CSF receptor triggers growth, and development of myeloid progenitor cells, mononuclear phagocytes and placental trophoblasts. The cfms gene-deficient mouse reveals that c-fms gene expression is required for the formation of mature phagocytic cells (Dai et al., 2002) . In addition to the role of M-CSF in phagocytic cell differentiation, M-CSF may have an inhibitory function in the early stage of hematopoietic cell differentiation. In embryonic stem (ES) cells, M-CSF inhibits differentiation into blood cells (Nakano et al., 1994) .
Fms tyrosine kinase was reported to interact with several SH2 domain-containing proteins, including the growth factor receptor-bound protein 2 (van der Geer and Hunter, 1993, Mancini et al., 1997) , STAT1 (Novak et al., 1996) , the p85 subunit of phosphatidylinositol 3 (PI3)-kinase (Reedijk et al., 1992) , the p120RasGTPase activating protein (Trouliaris et al., 1995) , phospholipase C-g (Bourette et al., 1997) , c-Src (Courtneidge et al., 1993) , Mona (Bourette et al., 1998) and c-Cbl (Mancini et al., 2002) . Recently, using yeast two-hybrid screening, we identified a novel Fms-interacting protein, termed FMIP, which interacted with activated Fms molecules (Tamura et al., 1999) . FMIP contains three potential nuclear localization signals (NLSs), a putative leucine zipper, a PEST domain and an Fms-interacting domain at the N-terminal end (Tamura et al., 1999) . Binding of FMIP to Fms tyrosine kinase was paralleled by rapid tyrosine phosphorylation within the binding domain, which drastically reduced its ability to associate with Fms. Furthermore, we showed that M-CSF treatment of the mouse myeloid progenitor cell line FDC-P1Mac11 (Gliniak and Rohrschneider, 1990 ) induces macrophage differentiation. Of key interest in terms of the specificity of type III receptor kinases is the fact that no association is seen between the SCF receptor and FMIP and FMIP is not influenced by addition of GM-CSF to cells (Tamura et al., 1999) . Thus, a potentially unique element to M-CSF signaling with respect to hematopoietic cell development may reside in the M-CSF effects on FMIP. Here, we have further investigated the role of FMIP in M-CSF action.
Results

FMIP is located in both cytoplasm and nucleus
FMIP forms a complex with the M-CSF receptor in FDC-P1Mac11 cells. This transient complex is coincident with tyrosine phosphorylation of the M-CSF receptor itself (Tamura et al., 1999) . FMIP is also tyrosine phosphorylated in these cells as a consequence of M-CSF addition. Thus, FMIP is a substrate for this kinase. A key question then is what can be the function of FMIP? To further elucidate the roles of FMIP on the molecular level, we compared the subcellular distribution of the endogenous FMIP in myeloid cells (FDCP1Mac11 cells) and in fibroblasts (NIH3T3 cells) by cell fractionation, as GFP fusion to FMIP created a toxic product within FDC-P1Mac11 cells. First, cell extracts were centrifuged at 850 g, and a pellet fraction (containing nuclei, data not shown) and a supernatant fraction were prepared and then lysed with Laemmli sample buffer. Aliquots were analysed by immunoblot using monoclonal antibody against FMIP. As control, we also employed anti-PU.1, p53, Erk1/2, PKCalpha and 130 kDa subunit of IL-3 receptor antibodies. As expected, PU.1 was detected in the pellet fraction (nuclear fraction), and the 130 kDa subunit of IL-3 receptor was detected in the supernatant fraction of FDC-P1Mac11 cells, indicating that plasma membrane was contained in this fraction (Figure 1 ). In this condition, both Erk1/2 and PKCalpha (known to be predominantly cytosolic) were detected in the supernatant fraction. As shown in Figure 1 , more than 70% of endogenous FMIP molecules were detected in the nuclear fraction in FDC-P1Mac11 cells in the presence of IL-3, and most of the molecules were detected in the nuclear fraction in NIH3T3 cells. To map the NLS in FMIP, we further examined microscopically using GFPfusion protein in living murine NIH3T3 cells.
FMIP protein was fused to GFP at the C-(FMIP(1-683)-GFP) or the N-terminal end (GFP-FMIP(1-683)) and expressed in mouse NIH3T3 cells ( Figure 2a ). As shown in Figure 2b , both are detected mainly in the nucleus, but a small amount of FMIP was also detected in the cytoplasm. FMIP contains three putative NLSs at amino-acid positions 7-10, 323-326 and 336-343 ( Figure 2a) . We then generated GFP-FMIPN(1-319), and FMIPN(1-319)-GFP. GFP-FMIPC(320-683) was found to be localized exclusively in the cytoplasm; however, GFP that was fused to FMIPN(1-319) at the N terminus or C terminus was detected mainly in the nucleus (Figure 2b ), suggesting that KKRK(7-10) (the number represents amino acids) may act as NLS.
To confirm these data, we replaced lysine 8 and arginine 9 with threonine and glycine, respectively (KR8,9TG-FMIP) and expressed the KR8,9TG-FMIP in mouse NIH3T3 cells. As shown in Figure 2c , most of the KR8,9TG-FMIP molecules were detected in the cytoplasm, indicating that KKRK(7-10) is responsible for the nuclear transport of FMIP molecules.
Thus, although there is strong evidence that FMIP is a substrate for a plasma membrane-bound kinase, we have found it to contain an extant nuclear localization sequence and be located to a great extent in the nucleus.
Activation of PKC can influence FMIP subcellular localization
The central role of protein kinase C (PKC) in macrophage differentiation has been well documented. Whetton et al. (1994) reported that M-CSF stimulation of enriched myeloid progenitor resulted in a nuclear translocation of PKCalpha and macrophage differentiation. Conversely, application of inhibitors of PKCalpha and simultaneous stimulation of these cells led to granulocyte differentiation (Pierce et al., 1998) . Expression of constitutively activated PKCalpha biases progenitor cells towards macrophage development. Furthermore, stimulation with M-CSF induces PKC activation (Datta et al., 1992) . We next used cell fractionation and microscopy to determine whether TPA, an activator of PKC, influences the subcellular localization of FMIP, another element in M-CSF signaling. NIH3T3 cells and FDC-P1Mac11 cells were stimulated with TPA for 15 min and then separated into nuclear and cytoplasmic fractions. Without TPA treatment, FMIP was detected mainly in the nuclear fractions in both cell lines, while after treatment with Since M-CSF also activates PKCalpha, we next examined the effects of M-CSF treatment on FMIP translocation. We did not detect a significant alteration of FMIP subcellular localization, suggesting that TPA induced more efficient activation of PKCalpha (data not shown) and that if there is an M-CSF effect it may be immeasurable due to the insensitivity of the assays we employed. Therefore, to further confirm the role of PKCalpha in FMIP nuclear translocation, we utilized wild-type PKCalpha and two PKC mutants, a kinase inactive mutant (K386R: lysine 386 was replaced by arginine) and a kinase active mutant (A25E, alanine 25 was replaced by glutamate). These wild type and mutants of PKCalpha were co-expressed with FMIP in the NIH3T3 cells. As expected, FMIP molecules were detected more in the cytoplasm in the presence of wildtype PKCalpha or PKC kinase active mutant (A25E), while FMIP was detected more in the nucleus in the presence of PKCalpha kinase inactive mutant (K386R) (Figure 3c ), indicating that enzymatic activity of PKC can lead to greater association of FMIP with the cytosol.
FMIP contains a critical nuclear localization sequence governed by PKC
In the light of the above data, we examined potential PKC phosphorylation sites on FMIP. Since two of the serine residues are located at amino-acid positions serine 5 and 6 (S5 and S6) in the flanking region of the NLS, KKRK(7-10), the phosphorylation of these serines may influence the nuclear transport of FMIP. To examine whether S5 and/or S6 are phosphorylated, we applied GST-FMIP fusion proteins containing GST-FMIP (1-154), GST-FMIP(1-57), GST-FMIP(S5A 1-57), GST-FMIP(S6A 1-57) and GST-FMIP(SS5,6AA 1-57) as substrates in an in vitro kinase assay. PKCalpha was first immunoprecipitated and was then employed in an in vitro kinase assay in the presence of Ca 2 þ and a lipid mixture (Gibco PKC assay kit). When serine 5 or 6 was replaced by alanine, the rate of phosphorylation was significantly reduced to about 50% of control values, and, when both serines were mutated, FMIP was no longer detectably phosphorylated by PKC (Figure 4a ). To examine whether both serines 5 and 6 indeed influence the nuclear transport of FMIP, we replaced both serine residues into alanine (SS5,6AA) or glutamate (SS5,6EE) (Morrison et al., 1993; Maciejewski et al., 1995) in the entire FMIP molecule. The wild type and mutant FMIP were expressed in the NIH3T3 cells with and without PKCalpha cDNA. In agreement with the data shown in Figure 3b , wild-type FMIP was detected mainly in the nucleus; however, when PKCalpha was overexpressed, FMIP molecules were detected more in the cytoplasm (Figure 4b ). Furthermore, FMIPSS5,6AA was detected exclusively in the nucleus, while FMIPSS5,6EE mimicking phosphorylated FMIP was detected exclusively in the cytoplasm, independent of the presence of PKCalpha (Figure 4b ). To confirm these data in the FDC-P1Mac11 cell system, we isolated 20 independent FDC-P1Mac11 cell lines each expressing MycHis-tagged wild-type FMIP, FMIPSS5,6AA and FMIPSS5,6EE, and subjected them to cell fractionation, followed by Myc-specific immunoblotting. In these transfectants, about 50% of the exogenous wild-type FMIP and FMIPSS5,AA were detected in the nuclear fraction, while more than 80% of FMIPSS5,6EE were detected in cytoplasmic fraction (Figure 4c ). These data suggest that PKC action influences FMIP subcellular localization. Three factors argue for a very dynamic situation with respect to FMIP localization and its regulation by PKC. First, as shown in Figure 4b , FMIPSS5,6AA mutants stay in the nucleus even in the presence of PKC, suggesting that FMIP phosphorylation is required for nuclear export. Second, when we applied the nuclear export inhibitor leptomycin B (LMB) to examine the FMIP and PKCalpha localization in TPA-treated cells, their cellular location was altered. As shown in Figure 5 , in the presence of LMB and TPA, both FMIP and PKCalpha accumulated in the nucleus. Third, since the half-life of FMIP is only 2 h (data not shown), the rate of FMIP turnover in this dynamic scenario may be critically regulated by phosphorylation. Furthermore, our lack of ability to see M-CSF-mediated translocation of FMIP may simply be a facet of a dynamic equilibrium where FMIP is constantly streaming between the nucleus and cytosol, and/or the proteasome.
FMIP phosphorylation by PKC alters its ability to mediate M-CSF signaling
To gain further insight into the molecular role of FMIP, we isolated three independent cell lines, #7, #13 and #15 expressing MycHis-tagged FMIP. As shown in Figure 6a , Myc-specific immunoblotting reveals that clone #15 expressed MycHis-tagged FMIP at about threefold greater levels than clone #13 and about twofold greater levels than clone #7. To compare the expression level of endogenous FMIP and MycHistagged FMIP, we applied a peptide-specific antibody against FMIP. Transfectants expressed 3-4-fold greater levels of FMIP than wild-type cells. We next examined the level of M-CSF receptors in the wild-type and FMIP-overexpressing FDC-P1Mac11 cell lines by c-Fms-specific immunoblot. In the presence of IL-3, c-Fms was detected at a low but similar level in all cell lines. The wild-type FDC-P1Mac11 cells grow in the presence of IL-3, and removal of IL-3 stops cell proliferation, followed by cell death within 3 days. M-CSF treatment rescues cells from cell death and simultaneously induces macrophage differentiation. We have previously reported that FMIP overexpression in FDC-P1Mac11 cells abrogates M-CSF-induced macrophage differentiation and, 4 days after M-CSF (2000 ED 50 ) treatment, about a half of the population became granulocytes (Tamura et al., 1999) . Therefore, FMIP-overexpressing FDC-P1Mac11 cells were examined microscopically 24 h after stimulation with M-CSF. No significant morphological differences were observed in any of the cell lines in the presence of IL-3. Unexpectedly, however, in the presence of 40 ng/ml (40 ED 50 ) of M-CSF, all the three FMIP-overexpressing cell lines, #7, #13 and #15, died within 24 h (Figure 6b) . Moreover, it has been previously reported that FDC-P1 cells proliferate upon stimulation with TPA (Ways et al., 1991) . We next examined whether TPA treatment alters the cell survival of FMIP-overexpressing cells. As expected, TPA or M-CSF treatment of the wild-type FDC-P1Mac11 cells induced cell proliferation and macrophage differentiation. Interestingly, treatment with TPA rescued all transfectants from cell death, however, did not induce macrophage differentiation (Figure 6b ). To further characterize the FMIP-overexpressing cells, we performed an apoptosis assay, TUNEL staining, after treatment with M-CSF and TPA for 36 h. Most of the M-CSF-treated FDCPMac11 cells were not stained by TUNEL, while 50% of FMIP-overexpressing cells became TUNEL staining positive even in the presence of M-CSF (Figure 7a,b) . Interestingly, in the presence of TPA, FMIP-overexpressing cells survived, even replicating more rapidly than wild-type FDC-P1Mac11 cells (Figure 7c ). We conclude that FMIP overexpression affects M-CSF signaling for survival and proliferation. 
Phosphorylation of regulatory serines in FMIP blocks its inhibitory effect on M-CSF-mediated cell survival and differentiation signaling
The above conclusion and the ability of the persistent activation of PKC via TPA addition to promote some of the effects seen with M-CSF even in the presence of high levels of FMIP supports the hypothesis that FMIP/PKC interaction is key in M-CSF signaling. As we reported above, overexpression of FMIP abrogated PKC activation by M-CSF, an effect not observed when TPA was present. We therefore tested this hypothesis with mutants of FMIP. The biological role of phosphorylation of serines 5 and 6 was assayed using the FDCP1Mac11 cell lines, each expressing MycHis-tagged FMIPSS5,6AA or FMIPSS5,6EE. As shown in Figure 8a , Myc-specific immunoblotting reveals that all transfectants expressed exogenous FMIP at similar levels ( Figure 8a ). No significant difference of growth rate was observed in any of the cell lines in the presence of IL-3. After withdrawal of IL-3 for 24 h, many dead cells were observed microscopically in all cell lines (Figure 8b ), treatment with TPA rescues all cells from cell death. However, after treatment with TPA for 48 h, untransfected cells and cells expressing FMIPSS5,6EE
showed dramatic morphological changes and gained CD11b surface expression about twofold more than cells expressing wild-type FMIP and FMIPSS5,6AA (Figure 8c ). Furthermore, M-CSF treatment failed to rescue cells expressing FMIP wild-type and FMIPS-S5,6AA from apoptosis (Figure 9 ), as shown by TUNEL staining, while untransfected cells and cells expressing FMIPSS5,6EE survived in the presence of M-CSF (Figure 8c ), suggesting that phosphorylation of regulatory serines of FMIP may contribute its inhibitory effect on both M-CSF-and TPA-mediated differentiation signal.
Discussion
We conclude from the above data that the PKCmediated phosphorylation of FMIP on serines 5 and 6 has a key role in promoting the growth and differentiation response to M-CSF seen in FDC-P1Mac11 cells. The ability of FMIP to perturb M-CSF signaling is intriguing and leads one to speculate that it may form a complex with PKCalpha to stifle activation of that kinase. However, our yeast two-hybrid analyses show that there is no association (in that particular assay) between FMIP and PKC. Other experiments are being pursued to analyse this further. M-CSF certainly activated PKC and PKCalpha certainly phosphorylates FMIP on key residues that govern subcellular localization. Further, we have shown that phosphomimetic substitutions of serines 5 and 6 can alleviate a blockade effect imposed by overexpression of FMIP on the actions of M-CSF with respect to its signaling for survival. Thus, we argue that we have evidence for a signaling pathway that is not activated by SCF/Kit receptor tyrosine kinase, and as such may be key in macrophage development. We can conclude this because SCF can stimulate neutrophilic Figure 5 Treatment of FMIP-overexpressing cells with Leptomycin B causes accumulation in the nucleus of FMIP and PKCalpha in the presence of TPA. cDNA encoding Myc-His-tagged wild-type FMIP was transfected into mouse NIH3T3 cells and cells were grown for 36 h. A sister culture was treated with 10 nM of LMB for 1 h and then, 15 min after treatment with and without TPA, cells were chemically fixed. After fixation, cells were stained by Myc-specific antibody, followed by TRITC-conjugated anti-mouse IgG and PKCalpha-specific antibody, followed by FITC-conjugated anti rabbit IgG Figure 6 Stimulation with M-CSF did not rescue FMIP-overexpressing cells from cell death after withdrawal of IL-3 without altering the level of M-CSF receptor expression. (a) Cell extracts from 2 Â 10 7 of wild-type FDC-P1 Mac11 and FMIP-overexpressing cell lines #7, #13 and #15 were divided into four aliquots. Three aliquots were analysed by immunoblot using anti-FMIP, anti-c-Fms and antiErk1/2 antibodies. One aliquot was immunoprecipitated by His antibody (IP anti-His) and then analysed by Myc-specific immunoblot. (b) Wild-type and FMIP-overexpressing FDC-P1Mac11 cells (#7, #13 and #15) were grown in the presence of IL-3 or M-CSF (40 ng/ml) with and without TPA (100 ng/ml) for 16 h. Cells were analysed in liquid culture by Hoffman modulation contrast microphotometry
FMIP interferes with M-CSF rescue of IL-3-deprived cells
A Mancini et al development from committed myeloid progenitors (Heyworth et al., 1992 , Whetton et al., 1994 , while from the same cells M-CSF promotes macrophage development. Also, SCF receptor does not associate with FMIP. Furthermore, in an SCF-and M-CSFresponsive myeloid cell line, we have shown that only M-CSF promotes FMIP phosphorylation (Whetton, unpublished data) . There are some hints, which suggest that FMIP phosphorylation is required for nuclear export. Firstly, FMIPSS5,6AA mutants stay in the nucleus even in the presence of PKC. Secondly, LMB and TPA treatment causes the co-localization of FMIP and PKCalpha in the nucleus, suggesting that it is not the case that newly synthesized FMIP is phosphorylated by PKCalpha and is accumulated in the cytoplasm. Thirdly, it has been well demonstrated that activated PKC translocated to the nucleus (Whetton et al., 1994; Wagner et al., 2000) . It is tempting to speculate that FMIP is phosphorylated while in the nucleus.
The molecular mechanisms of the inhibitory effects of FMIP in M-CSF-mediated survival signaling are still unclear. Recently, we found that FMIP collaborates with PU.1 that is required for macrophage differentiation (Zhang et al., 1996 , Petrovick et al., 1998 , Tagoh et al., 2002 , measured by transactivation of mouse cfms promoter (Tamura unpublished data) , suggesting that FMIP may be the regulator of several transcription factors. Interestingly, there are some hints that, in addition to the role of M-CSF in phagocytic cell differentiation, M-CSF may have an inhibitory function in the early stage of hematopoietic cell differentiation (Nakano et al., 1994) . These authors showed that, in the in vitro differentiation system using ES cells that transform into blood cells, the total number of colonies was much lower in the presence of stroma cells that produced M-CSF than in the presence of stroma cells derived from OP/OP mice (Marks and Lane, 1976 ) that lack M-CSF (Yoshida et al., 1990) . Indeed, FMIP is highly expressed in immature cells (Tamura and Whetton, unpublished data) . Our working hypothesis is that FMIP is a high turnover protein with a role in vectorial flow of information from occupied receptors to transcription factor. FMIP is regulated by phosphorylation and it is potentially critical in M-CSF signaling. Further work will identify the mechanism of these effects and the potential role of FMIP as a substrate for leukemogenic tyrosine kinases such as HIP1/PDGFRb, TEL/ PDGFRb and Flt3/ITD, proteins related to the M-CSF receptor.
Materials and methods
Plasmid constructions
Green fluorescent protein (GFP)-FMIP fusion proteins were generated in the pEGFP system (BD Clontech, Palo Alto, CA, USA). To generate MycHis-tagged FMIP, the EcoRI-DraI (1-2047) fragment of hFMIP cDNA (Xie et al., 1993) was cloned into pcDNA3.1/Myc-His (Invitrogen, Carlsbad). The PKCalpha wild type, its kinase negative mutant (K368R) and kinase active mutant (A25E) cDNA (Wagner et al., 2000) in pRc/CMV were provided by S Ludwig (University Duesseldorf, Germany).
Cells and antibodies
Mouse NIH3T3 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) FCS. FDC-P1Mac11 cells were maintained in the same medium, supplemented with WEHI3BD-conditioned medium as a source of IL-3, and applied at a concentration that stimulated optimal cell growth. M-CSF (R & D systems, Wiesbaden, Germany) was added at 40 ng/ml (40ED 50 ) or 100 ng/ml. Monoclonal antibodies against Myc-epitope (9E10), polyclonal antibodies against His-epitope, PKCalpha, p53, PU.1, 130 kDa subunit of IL-3 receptor and Fms were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), respectively. FMIP peptide-specific antibody was from BioCarta (Carlsbad, CA, USA) and monoclonal antibody against FMIP, F6cl, was raised in the Leukemia Research Fund Antibody Facility (Oxford, UK) in collaboration with one of the authors (AW). Erk1/2, was from Cell Signaling Technology (Beverly, MA, USA). FITC anti-mouse CD11b was from Pharmingen (San Diego, CA, USA).
Subcellular fractionation
Cells were suspended in the fractionation buffer containing 5 mM Tris-HCl (pH 7.4), 5 mM KCl, 1.5 mM MgCl 2 , 0.1 mM EGTA, 1 mM DTT, 0.2 mM PMSF, 2 mM benzamidine and 5% (w/v) Trasylol. For NIH3T3 cell fractionation, 0.1%NP40 was added into suspension, and for FDC-P1Mac11 cell 
TUNEL assay
Cells were fixed with 2% paraformaldehyde (PFA) and applied for TUNEL assay. TUNEL assay was performed with an In Situ Cell Death Detection Kit, TMR red, as described by the manufacturer (Roche Diagnostics GmbH, Penzberg, Germany).
Immunoprecipitation and immunoblotting
Details of immunoblotting and immunoprecipitation have been published previously (Tamura et al., 1999) .
Generation of FMIP-overexpressing FDC-P1Mac11 cells
Transfection of FDC-P1Mac11 cells with pFMIP/Myc-His, pFMIPSS5,6EE/Myc-His and pFMIPSS5,6AA/Myc-His DNA was performed with the Polyfectt reagent, as described by the manufacturer (Qiagen, Hilden, Germany). In all, 20 different neomycin-resistant cell clones for each were obtained by growth in G418-containing selection medium and limiting dilution. Individual clones showed identical dependency on IL-3 for growth.
